|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 114,400 KRW | -1.97% |
|
-1.12% | -8.84% |
| 06-10 | FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A | CI |
| 05-20 | Gc Biopharma and Novel Pharma Announce Sanfilippo Syndrome Treatment Obtains FDA IND Approval | CI |
GC Biopharma Corp. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was KRW 0.00006 million compared to KRW 0.00001 million a year ago.
Net loss was KRW 25,312.53 million compared to KRW 22,452.87 million a year ago. Basic loss per share from continuing operations was KRW 2,218 compared to KRW 1,967 a year ago. Basic loss per share was KRW 2,218 compared to KRW 1,967 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.84% | 939M | |
| +51.63% | 796B | |
| +41.51% | 628B | |
| -5.10% | 358B | |
| +19.90% | 331B | |
| +9.95% | 301B | |
| +17.66% | 244B | |
| +3.39% | 228B | |
| +10.75% | 214B | |
| +6.99% | 165B |
GC BIOPHARMA CORP. 
